

MultiColi™

Multi-Protein Expression in *E. coli*



User Manual

Version 5.0

TABLE OF CONTENTS

A. MultiColi™ Kit Contents	- 1 -
B. Introduction	- 2 -
C. The MultiColi™ System	- 3 -
C.1. Synopsis	- 3 -
C.2. MultiColi™ Vectors	- 4 -
C.3 The multiple integration element (MIE)	- 5 -
C.4 Tags, promoters, terminators	- 5 -
C.5. Generating Plasmid Constructs for Complex Expression	- 6 -
C.6. Complex Expression	- 7 -
D. Procedures	- 9 -
D.1. Cloning into MultiColi™ vectors	- 9 -
D.1.1. Single gene insertion into the MIE by SLIC	- 9 -
D.1.2. Polycistron assembly in MIE by SLIC	- 18 -
D.1.3. Gene insertion by restriction/ligation	- 20 -
D.1.4. Multiplication by using the HE and BstXI sites	- 23 -
D.2. Cre-LoxP reaction of Acceptors and Donors	- 26 -
D.2.1. Cre-LoxP fusion of Acceptors and Donors	- 28 -
D.2.2. Deconstruction of fusion vectors by Cre	- 31 -
D.3. Co-expression by Co-transformation	- 34 -
E. MultiColi™ multi-gene combination: Examples	- 35 -
E.1. SLIC cloning into MultiColi™ vectors: human TFIIIF	- 35 -

E.2. The Homing endonuclease/BstXI module: yeast RES complex	- 36 -
F. Appendix	- 37 -
F.1. DNA sequence of MIE	- 37 -
F.2. DNA sequences of MultiColi™ vectors	- 38 -
F.3. MultiColi™ plasmid maps	- 39 -
F.4. Analytical restriction of MultiColi™ vectors	- 40 -
G. References	- 41 -
H. Purchaser Notification	- 42 -

MultiColi™ Kit Contents:

- **Plasmid acceptor vectors**

pACE1, pACE2 – approx. 5 µg DNA per vial (in buffer solution)

keep at 4°C for short-term storage and in a freezer at -20°C or lower for medium- and long-term storage (take care to avoid repeated freeze-thaw cycles, e.g. by aliquotting DNA prior to freezing)

- **Plasmid donor vectors**

pDC, pDK, pDS – approx. 5 µg DNA per vial (in buffer solution)

keep at 4°C for short-term storage and in a freezer at -20°C or lower for medium- and long-term storage (take care to avoid repeated freeze-thaw cycles, e.g. by aliquotting DNA prior to freezing)

- **E. coli strains as agar stabs**

a) pirLC, pirHC cells[†]

[†] *E. coli* strains expressing the *pir* gene product for propagation of donor vectors (any other strain with *pir*⁺ background can be used as well). LC: low copy number propagation, HC: high copy number propagation of plasmids with R6Kγ origin.

Additionally required reagents:

Antibiotics: ampicillin, chloramphenicol, kanamycin, spectinomycin, tetracycline

Enzymes: Cre recombinase

T4 DNA polymerase (for recombination insertion of genes)

Phusion polymerase or any other proof-reading DNA polymerase (for PCR amplification of DNA)

Restriction enzymes and T4 DNA ligase (for restriction-ligation cloning)

Standard laboratory *E. coli* strain for cloning (TOP10, HB101, DH5α)

Expression strain(s) of choice, e.g. BL21(DE3), Rosetta, AD494, Origami (DE3), etc.

Choice of strain will depend on your target protein and its underlying DNA sequence.

B. Introduction

Protein complexes are the heart and soul of many cellular processes¹. Some researchers go as far as describing the cell as “a collection of protein machines”² which predominantly are multi-protein complexes. Whether you think of replication, transcription³, translation⁴, DNA repair, the processing, import, trafficking and export of proteins or other biomolecules, or the maintenance of the structural stability and integrity of any cell, multi-subunit protein assemblies play an important role in all these biological phenomena. In addition, other processes such as entry of viruses into human cells, also critically hinge on the co-operation of proteins or protein complexes⁵.

Various prokaryotic microorganisms, *E. coli* being the prototypical workhorse, are harnessed to express heterologous proteins and protein complexes and also to cost-efficiently produce established or novel compounds by means of metabolic engineering⁶. Scientists wishing to study these processes in functional and structural detail often require significant amounts of the protein complexes under investigation. While obtaining bulk protein usually is not a problem for protein complexes that are abundant in a steady-state or a developing/differentiating cell, this becomes more difficult for complexes that are transient in nature, appear only periodically in cells or simply occur only in low amounts. In such cases, systems come in handy that allow homo- or heterologous expression of these complexes in large amounts.

While various methods and systems have been developed to address this problem, most of them are of little use for intense research efforts directed at generating and investigating scores of protein complexes in parallel, i.e. in an automated fashion. Such a system should be robust and easy-to-install in terms of manipulation steps / protocols and/or components used in the process⁷. The MultiColi™ system exactly addresses

¹ Robinson et al., *Nature* **450**, 973 (2007); Charbonnier S et al., *Biotechnol Annu Rev* **14**, 1 (2008).

² Alberts, *Cell* **92**, 291 (1998).

³ Van Hijum et al., *Microbiol Mol Biol Rev* **73**, 481 (2009).

⁴ Estrozi et al., *Nat Struct Mol Biol* **18**, 88.

⁵ Bhattacharya, *Nature* **459**, 24 (2009).

⁶ Chemler and Koffas, *Curr Opin Biotech* **19**, 597 (2008); Chou, *Appl Microbiol Biotech* **76**, 521 (2007); Lee et al., *Curr Opin Biotech* **19**, 553 (2008).

⁷ Nie et al., *Curr Genomics* **10**: 558-72 (2009).

these needs and avoids some problems that occur with *in vitro* reconstitution of protein complexes from individually or co-expressed protein components reconstitution of protein complexes from individually or co-expressed protein components.

C. The MultiColi™ system

C.1. Synopsis

MultiColi™ is a 3rd generation multi-gene expression system for complex production in *E. coli*, created at the European Molecular Biology Laboratory (EMBL) Grenoble outstation. MultiColi™ can be applied both manually and also in an automated set-up by using a liquid handling workstation. MultiColi™ applies tandem recombination steps for rapidly assembling many genes into multi-gene expression cassettes. These can be single or polycistronic expression modules, or a combination of these elements. MultiColi™ also offers the option to employ conventional approaches involving restriction enzymes and ligases if desired, which may be the methods of choice in laboratories not familiar with recombination approaches. The following strategies for multi-gene assembly and expression are provided for in the MultiColi™ system and detailed in **Section C** and **Section D**:

- (1) Single gene insertions into vectors (recombination or restriction/ligation)
- (2) Multi-gene assembly into a polycistron (recombination or restriction/ligation)
- (3) Multi-gene assembly using homing endonucleases
- (4) Multi-gene plasmid fusion by Cre-LoxP reaction
- (5) Multi-gene expression by cotransformation

These strategies can be used individually or in conjunction, depending on the project and user. In **Section D**, step-by-step protocols are provided for each of the methods for multi-gene cassette assembly that can be applied in the MultiColi™ system. Each procedure is illustrated by corresponding complex expression experiments in **Section E** of this Manual. DNA sequences of MultiColi™ vectors are provided in the Appendix. Sequences in electronic format can be requested from www.geneva-biotech.com.

C.2. MultiColi™ vectors

At the core of the technology are five small *de novo* designed vectors which are called “Acceptor” and “Donor” vectors (see **Illustration 1**). Acceptor vectors (pACE1, pACE2) contain origins of replication derived from ColE1 (low to medium copy) and resistance markers (ampicillin or tetracycline). Donor vectors contain conditional origins of replication (derived from phage R6K γ), which make their propagation dependent on hosts expressing the *pir* gene. Donor vectors contain resistance markers kanamycin, chloramphenicol, or spectinomycin. Up to three Donor vectors can be used in conjunction with one Acceptor vector.





Illustration 1: MultiColi™ system for Multi Protein Co-Expression

All Donor and Acceptor vectors contain a loxP imperfect inverted repeat and in addition, a multiple integration element (MIE). This MIE consists of an expression cassette with a promoter of choice (prokaryotic, mammalian, insect cell specific or a combination thereof, depending on the MultiColi™ system) and a corresponding terminator (if required, e.g. the lac promoter does not require a matching terminator). These flank a DNA segment that contains a number of restriction sites which can be used for conventional cloning approaches or also for generating double-strand breaks for the integration of expression elements of choice (further promoters, ribosomal binding sites, terminators and genes). The MIE is completed by a homing endonuclease site and a specifically designed

restriction enzyme site (BstXI) flanking the promoter and the terminator (see **C.2**) Vector DNA sequences are provided in the Appendix. Maps of all vectors are shown at the end of this manual.

C.3. The multiple integration element (MIE)



The MIE was derived from a polylinker⁸ and allows several approaches for multi-gene assembly (**Section D**). Multiple genes can be inserted into the MIE of any one of the vectors by a variety of methods, for example BD-In-Fusion recombination⁹ or SLIC (sequence and ligation independent cloning)¹⁰. For this, the vector needs to be linearized. This can be carried out efficiently by PCR reaction with appropriate primers since the vectors are all small (2 to 3 kb). Use of ultra high-fidelity polymerases such as Phusion¹¹ is recommended. Alternatively, if more conventional approaches are preferred, i.e. in a regular wet lab setting without robotics, the vectors can also be linearized by restriction digestion, and a gene of interest can be integrated by restriction / ligation (**Section D**). The DNA sequence of the MIE is shown in the **Appendix**.

C.4. Tags, promoters, terminators

Current vectors of the MultiColi™ system for *E. coli* contain the default promoters T7 and Lac, as well as the T7 terminator element (**Illustrations 1, 10**). The T7 system is currently

⁸ Tan et al. *Protein Expr. Purif.* **40**, 385 (2005)

⁹ ClonTech TaKaRa Bio Europe, www.clontech.com

¹⁰ Li and Elledge, *Nat. Methods* **4**, 251 (2007)

¹¹ Finnzymes/New England BioLabs, www.neb.com

most commonly used; it requires bacterial strains which contain a T7 polymerase gene in the *E. coli* genome. The Lac promoter is a strong endogenous promoter which can be utilized in most strains. All MultiColi™ vectors contain the lac operator element for repression of heterologous expression.

All promoters and terminators present in MultiColi™ Donor and Acceptor vectors, and in fact the entire multiple integration element (MIE) can be exchanged with a favored expression cassette by using restriction/ligation cloning with appropriate enzymes (for example ClaI/PmeI, **Illustration 2**) or insertion into linearized MultiColi™ vectors where the MIE was removed by sequence and ligation independent approaches such as SLIC (sequence and ligation independent cloning). In an experimental variation the T7 promoter in pDC was substituted with a trc promoter (pDC^{trc}) and the T7 promoter in pACE with an arabinose promoter (pACE^{ara}). The resulting vectors were used successfully in co-expression experiments by inducing with arabinose and IPTG.

Currently, the MultiColi™ system vectors do not contain DNA sequences encoding for affinity tags that enable purification or solubilization of the protein(s) of interest. We typically use C- or N-terminal oligohistidine tags, with or without protease sites for tag removal. We introduce these by means of the respective PCR primers used for amplification of the genes of interest prior to SLIC mediated insertion. We recommend outfitting Donors or Acceptors of choice by the array of custom tags that are favored in individual user laboratories prior to inserting recombinant genes of interest. This is best done by a design which will, after tag insertion, still be compatible with the recombination based principles of MultiColi™ system usage.

C.5. Generating Plasmid Constructs for Complex Expression

To create your expression constructs (see **illustration 3**), introduce your gene or genes of interest - carrying any additional modifications such as purification or reporter tags - using your method of choice (conventional restriction-ligation cloning or SLIC) into any of the acceptor or donor vectors. You can then create acceptor- donor fusions with the help of Cre recombinase. Note that you need at least one acceptor vector if you wish to amplify the multi-gene constructs in standard laboratory strains. Select your multi-vector multi-gene fusions by subjecting transformed bacteria to multiple antibiotic

selection on agar and/or multi-well plates. You will then have to extract the plasmid construct from your host strains since the expression strain will most likely be different (see **Section C.5**).




Illustration 3: Schematic representation of process for generating multi-gene expression constructs.

If, for example, you require an antibiotic resistance marker change, you can transfer entire expression cassettes (including promoters and terminators) from acceptor to acceptor or donor to donor by employing the homing endonuclease- BstXI module. Note that you cannot move cassettes from acceptors to donors or vice versa since their homing endonuclease and BstXI recognition sites are incompatible.

C.6. Complex Expression

For expression in *E. coli*, the MultiColi™ multi-gene expression vector fusions with appropriate promoters or terminators are transformed into the appropriate expression host of choice. In the current version (T7 and lac promoter elements), most of the wide array of currently available expression strains can be utilized. If particular expression

strains already contain helper plasmids with DNA encoding for chaperones, lysozyme or other factors of interest, the design of the multi-gene fusion should ideally be such that the MultiColi™ vector containing the resistance marker that is also present on the helper plasmid is not included in multi-gene vector construction to avoid issues with plasmid incompatibility (although this is probably not essential).

Alternatively, the issue can be resolved by creating new versions of the MultiColi™ vectors containing resistance markers that circumvent the conflict. This can be easily performed by PCR amplifying the vectors minus the resistance marker, and combine the resulting fragments with a PCR amplified resistance marker by recombination (SLIC) or blunt-end ligation (using 5′phosphorylated primers). Note that resistance markers can also be exchanged in between MultiColi™ vectors by restriction digestion with AlwNI and ClaI (for Donors) and AlwNI and PmeI (for Acceptors).


Donor vectors depend on the *pir* gene product expressed by the host, due to the R6Ky conditional origin of replication. In regular expression strains, they rely on fusion with an Acceptor for productive replication. Donors or Donor-Donor fusions can nonetheless be used even for expression when not fused with an Acceptor, by using expression strains carrying a genomic insertion of the *pir* gene. Such strains have recently become available (e.g. from Novagen Inc., Madison WI, USA).

Co-transformation of two plasmids can also lead to successful protein complex expression. The MultiColi™ system contains two Acceptor vectors, pACE and pACE2, which are identical except for the resistance marker (**Illustration 1**). Therefore, genes present on pACE1 or pACE2, respectively, can be expressed by co- transformation of the two plasmids and subsequent simultaneous exposure to tetracyclin and ampicillin. In fact, entire Acceptor-Donor fusions containing several genes, based on pACE1 or pACE2 as Acceptors, can in principle be co-transformed for multi-expression, if needed.

D. Procedures

D.1. Cloning into MultiColi™ vectors

All Donors and Acceptors contain an identical MIE with exception of the homing endonuclease site / BstXI tandem that flanks the MIE (Illustrations 1 and 3, plasmid maps in the appendix). The MIE is tailored for sequence and ligation independent gene insertion methods. In addition, the MIE also contains a series of unique restriction sites, and therefore can be used as a classical polylinker for conventional gene insertion by restriction/ligation. We suggest to choose the methods a user lab is most familiar with. For automated applications, restriction/ligation is essentially ruled out. In this case, recombination approaches can be used efficiently for gene insertion (SLIC).



D.1.1. Single gene insertion into the MIE by SLIC

Several procedures for restriction/ligation independent insertion of genes into vectors have been published or commercialized (Novagen LIC, Becton-Dickinson BD In-Fusion and others), each with its own merit. All of these systems rely on the exonuclease activity of DNA polymerases. In the absence of dNTPs, 5' extensions are created from blunt ends or overhangs by digestion from the 3' end. If two DNA fragments contain the same approx. 20 bp sequence at their termini at opposite ends, this results in overhangs that share

complementary sequences capable of annealing. This can be exploited for ligation independent combination of two or several DNA fragments containing homologous sequences.

If T4 DNA polymerase is used, this can be carried out in a manner that is independent of the sequences of the homology regions (Sequence and Ligation Independent Cloning, SLIC) and detailed protocols have become available. In the context of multi-protein expression, this is particularly useful, as the presence of unique restriction sites, or their creation by mutagenesis, in the ensemble of encoding DNAs ceases to be an issue.

We adapted SLIC for the insertion of encoding DNAs amplified by Phusion polymerase into the MultiColi™ Acceptor and Donor vectors according to the published protocols. This not only allows seamless integration of genes into the expression cassettes, but also concatamerization of expression cassettes into multi- gene constructs via a simple and repetitive routine that can be readily automated.




Illustration 5: Single gene insertion by SLIC. A gene of interest (GOI 1) is PCR amplified with specific primers and integrated into a vector (Acceptor, Donor) linearized by PCR with complementary primers (complementary regions are shaded in light gray or dark grey, respectively). Resulting PCR fragments contain homology regions at their ends. T4 DNA polymerase acts as an exonuclease in the absence of dNTP and produces long sticky overhangs. Mixing (optionally annealing) of T4DNA polymerase exonuclease treated insert and vector is followed by transformation, yielding a single gene expression cassette.

We use an improved protocol for SLIC which was modified from the original publication¹². This protocol, as applied manually, is detailed below (Protocol 1). If other systems are used (BD-InFusion etc.), follow the manufacturer's recommendations. For robotics applications, modifications of the protocol may be necessary and will be detailed elsewhere¹³.

Protocol 1: Single gene insertion by SLIC.

Reagents required:

Phusion Polymerase

5x HF Buffer for Phusion Polymerase

dNTP mix (10 mM)

T4 DNA polymerase (and 10x Buffer)

DpnI enzyme

E. coli competent cells

100mM DTT, 2M Urea, 500 mM EDTA

Antibiotics

Step 1: Primer design

Primers for the SLIC procedure are designed to provide the regions of homology that result in long sticky ends after treatment with T4 DNA polymerase in the absence of dNTP:

Primers for the insert contain a DNA sequence corresponding to this region of homology ("Adaptor sequence" in Illustration 4, inset), followed by a sequence stretch that specifically anneals to the insert to be amplified (**Illustration 5**, inset). Useful adaptor sequences for SLIC are listed below (**Table I**). If the gene of interest (GOI) is amplified from a vector already containing expression elements (e.g. the pET vector series), this "insert specific sequence" can be located upstream of a ribosome binding site (rbs). Otherwise, the forward primer needs to be designed such that a ribosome binding site is also provided in the final construct (**Illustration 5**, inset).

¹²Li and Elledge, *Nat. Methods* **4**, 251 (2007)

¹³Bieniossek, Nie et al., *Nat. Methods* **6**, 447 (2009).

Step 2: PCR amplification of insert and vector

Identical reactions are prepared in 100- μ l volume for DNA insert to be cloned and vector to be linearized by PCR:

ddH ₂ O	75 μ l
5 \times Phusion HF Reaction buffer	20 μ l
dNTPs (10 mM stock)	2 μ l
Template DNA (100 ng/ μ l)	1 μ l
5' SLIC primer (100 μ M stock)	1 μ l
3' SLIC primer (100 μ M stock)	1 μ l
Phusion polymerase (2 U/ μ l)	0.5 μ l

PCR reactions are then carried out with a standard PCR program (unless very long DNAs are amplified, in which case you should the double extension time):

1 x 98° C for 2 min
 30 x [98° C for 20 sec. -> 50° C for 30 sec. -> 72° C for 3 min]
 Hold at 10° C

Analysis of the PCR reactions by agarose gel electrophoresis and ethidium bromide staining is recommended.

Step 3: DpnI treatment of PCR products (optional)

PCR reactions are then supplied with 1 μ l DpnI enzyme which cleaves parental plasmids (that are methylated). For insert PCR reactions, DpnI treatment is not required if the resistance marker of the template plasmid differs from the destination vector.

Reactions are carried out as follows:

Incubation: 37° C for 1-4h
 Inactivation: 80° C for 20 min

Step 4: Purification of PCR products

! PCR products must be purified to remove residual dNTPs!

Otherwise, the T4 DNA polymerase reaction (Step 5) may be compromised. Product purification is best performed by using commercial PCR Purification Kits or NucleoSpin Kits (Qiagen, MacheryNagel or others). It is recommended to perform elution in the minimal possible volume indicated by the manufacturer.

Step 5: T4 DNA polymerase exonuclease treatment

Identical reactions are prepared in 20- μ l volume for insert and for vector (eluted in Step 4):

10x T4 DNA polymerase buffer	2 μ l
------------------------------	-----------

100mM DTT	1 μ l
2M Urea	2 μ l
DNA eluate from Step 3 (vector or insert)	14 μ l
T4 DNA polymerase	1 μ l

Reactions are then carried out as follows:

Incubation: 23°C for 20 min

Arrest: Addition of 1 μ l 500 mM EDTA

Inactivation: 75°C for 20 min

Step 6: Mixing and Annealing

Exonuclease treated insert and vector are then mixed, followed by an (optional) annealing step which was found to enhance efficiency¹⁴:

T4 DNA pol treated insert: 10 μ l

T4 DNA pol treated vector: 10 μ l

Annealing: 65°C for 10 min

Cooling: Slowly (in heat block) to RT

Step 7: Transformation

Mixtures are next transformed into competent cells following standard transformation procedures.

Reactions for pACE1 and pACE2 derivatives are transformed into standard *E. coli* cells for cloning (such as TOP10, DH5 α , HB101) and after recovery (2-4h) plated on agar containing ampicillin (100 μ g/ml) or tetracycline (25 μ g/ml), respectively.

Reactions for Donor derivatives are transformed into *E. coli* cells expressing the *pir* gene (such as BW23473, BW23474, or PIR1 and PIR2, Invitrogen) and plated on agar containing chloramphenicol (25 μ g/ml, pDC), kanamycin (50 μ g/ml, pDK), and spectinomycin (50 μ g/ml, pDS).

Step 8: Plasmid analysis


Plasmids are cultured in small-scale in media containing the corresponding antibiotic, and analyzed by sequencing and (optionally) restriction mapping with an appropriate restriction enzyme.

¹⁴ Dr. Rolf Jaussi, PSI Villigen, personal communication

D.1.2. Polycistron assembly in MIE by SLIC

The multiple integration element can also be used to integrate genes of interest by using multi-fragment SLIC recombination as shown in **Illustration 6**. Genes preceded by ribosome binding sites (rbs) can be assembled into polycistrons in this way.

Illustration 6: Generating a polycistron by SLIC. Genes of interest (GOI 1,2,3) are PCR amplified with specific primers and integrated into a vector (Acceptor, Donor) linearized by PCR with primers complementary to the ends of the forward primer of the first (GOI 1) and the reverse primer of the last (GOI 3) gene to be assembled in the polycistron (complementary regions are shaded in light gray or dark grey, respectively). Resulting PCR fragments contain homology regions at the ends. T4 DNA polymerase acts as an exonuclease in the absence of dNTP and produces long sticky overhangs. Mixing (optionally annealing) of T4DNA polymerase exonuclease treated insert and vector is followed by transformation, yielding a polycistronic expression cassette.



Protocol 2. Polycistron assembly by SLIC. Reagents required:

- Phusion Polymerase
- 5x HF Buffer for Phusion Polymerase
- dNTP mix (10 mM)
- T4 DNA polymerase (and 10x Buffer)
- E. coli* competent cells
- 100mM DTT, 2M Urea, 500 mM EDTA
- Antibiotics

Step 1: Primer design

The MIE element is composed of tried-and-tested primer sequences. These constitute the “Adaptor” sequences that can be used for inserting single genes or multi-gene constructs. Recommended adaptor sequences are listed below (**Table I**).

Adaptor sequences form the 5' segments of the primers used to amplify DNA fragments to be inserted into the MIE. Insert specific sequences are added at 3', DNA encoding a ribosome binding site can be inserted optionally if not already present on the PCR template

Step 2: PCR amplification of insert and primer

Identical reactions are prepared in 100- μ l volume for all DNA insert (GOI 1,2,3) to be cloned and the vector to be linearized by PCR:

ddH ₂ O	75 μ l
5 \times Phusion HF Reaction buffer	20 μ l
dNTPs (10 mM stock)	2 μ l
Template DNA (100 ng/ μ l)	1 μ l
5' SLIC primer (100 μ M stock)	1 μ l
3' SLIC primer (100 μ M stock)	1 μ l
Phusion polymerase (2 U/ μ l)	0.5 μ l

PCR reactions are then carried out with a standard PCR program (unless very long DNAs are amplified, in which case you should double the extension time):

1 x 98° C for 2 min

30 x [98° C for 20 sec. -> 50° C for 30 sec. -> 72° C for 3 min]

Hold at 10° C

Analysis of the PCR reactions by agarose gel electrophoresis and ethidium bromide staining is recommended.

Step 3: DpnI treatment of PCR products (optional)

PCR reactions are then supplied with 1 μ l DpnI enzyme which cleaves parental plasmids (that are methylated). For insert PCR reactions, DpnI treatment is not required if the resistance marker of the template plasmids differs from the destination vector.

Reactions are then carried out as follows:

Incubation: 37°C for 1-4h
 Inactivation: 80°C for 20 min

Step 4: Purification of PCR products

! PCR products must be purified to remove residual dNTPs !

Otherwise, the T4 DNA polymerase reaction (Step 5) may be compromised.

Product purification is best performed by using commercial PCR Purification Kits or NucleoSpin Kits (Qiagen, MacheryNagel or others). It is recommended to perform elution in the minimal possible volume indicated by the manufacturer.

Step 5: T4 DNA polymerase exonuclease treatment

Identical reactions are prepared in 20- μ l volume for each insert (GOI 1,2,3) and for the vector (eluted in Step 4):

10x T4 DNA polymerase buffer	2 μ l
100mM DTT	1 μ l
2M Urea	2 μ l
DNA eluate from Step 3 (vector or insert)	14 μ l
T4 DNA polymerase	1 μ l

Reactions are then carried out as follows:

Incubation: 23°C for 20 min
 Arrest: Addition of 1 μ l 500 mM EDTA
 Inactivation: 75°C for 20 min

Step 6: Mixing and Annealing

T4 DNA polymerase exonuclease treated insert and vector are then mixed, followed by an (optional) annealing step which was found to enhance efficiency¹⁵:

T4 DNA pol treated insert 1 (GOI 1):	5 μ l
T4 DNA pol treated insert 2 (GOI 2):	5 μ l
T4 DNA pol treated insert 3 (GOI 3):	5 μ l
T4 DNA pol treated vector:	5 μ l

Annealing: 65°C for 10 min
 Cooling: Slowly (in heat block) to RT

Step 7: Transformation

Mixtures are next transformed into competent cells following standard transformation procedures.

¹⁵ Dr. Rolf Jaussi, PSI Villigen, personal communication

Reactions for pACE1 and pACE2 derivatives are transformed into standard *E. coli* cells for cloning (such as TOP10, DH5 α , HB101) and after recovery plated on agar containing ampicillin (100 μ g/ml) or tetracycline (25 μ g/ml), respectively.

Reactions for Donor derivatives are transformed into *E. coli* cells expressing the *pir* gene (such as BW23473, BW23474, or PIR1 and PIR2, Invitrogen) and plated on agar containing chloramphenicol (25 μ g/ml, pDC), kanamycin (50 μ g/ml, pDK), and spectinomycin (50 μ g/ml, pDS).

Step 8: Plasmid analysis

Plasmids are cultured and correct clones are selected based on specific restriction digestion and DNA sequencing of the inserts.

Table I. Adaptor sequences

For single gene or multi-gene insertions into MultiColi™ vectors by SLIC.

Adaptor ¹	Sequence	Description
T7InsFor	TAGGTATCGATAATACG ACTCACTATAGGG	Forward primer for <u>insert</u> amplification, if gene of interest (GOI) is present in a T7 system vector (i.e. pET series). No further extension (rbs, insert specific overlap) required.
T7InsRev	CCTCAAGACCCGTTTAGA GGCCCAAGGGTTATG CTAG	Reverse primer for <u>insert</u> amplification, if GOI is present in a T7 system vector (i.e. pET series). No further extension (stop codon, insert specific overlap) required.
T7VecFor	CTAGCATAACCCCTGGG GCCTCTAAACGGGTCTT AGG	Forward primer for <u>vector</u> amplification, reverse complement of T7InsRev. No further extension required.
T7VecRev	CCCTATAGTGAGTCGTAT TATCGATACCTA	Reverse primer for <u>vector</u> amplification, reverse complement of T7InsFor. No further extension required.
NdeInsFor	GTTTAACTTTAAGAAGGA GATATACATATG	Forward primer for <u>insert</u> amplification for insertion into MIE site I1 (Illustration 2). Further extension at 3' (insert specific overlap) required. Can be used with adaptor XhoInsRev in case of single fragment SLIC (Illustr. 3).
XhoInsRev	pACE1,pACE2,pDC (T7): CTTTGTTAGCAGCCGGAT CTCTCGAG pDK,pDS (lac): GGGTTTAAACGGAECTA GTCTCGAG	Reverse primer for <u>insert</u> amplification for insertion into MIE site I4 (Illustr. 2). Further extension at 3' (stop codon, insert specific overlap) required. Can be used with adaptor NdeInsFor in case of single fragment SLIC (Illustr. 3).

XhoVecFor	pACE1,pACE2,pDC (T7): CTCGAGAGATCCGGCTG	Forward primer for <u>vector</u> amplification, reverse complement of XhoInsRev
	CTAACAAAG pDK,pDS (Iac): CTCGAGACTAGTTCCG TTTAAACCC	No further extension required.
NdeVecRev	CATATGTATATCTCCT TCTTAAAGTTAAAC	Reverse primer for <u>vector</u> amplification, reverse complement of NdeInsFor. No further extension required.
SmaBam	GAATTCAGTGGCCGT CGTTTTACAGGATCC	Reverse primer for <u>insert</u> amplification (GO11) for insertion into MIE site I1 (Illustr. 2). Further extension at 3' (stop codon, insert specific overlap) required. Use with adaptor NdeInsFor.
BamSma	GGATCCTGTAAAC GACGGCCAGTGAAT TC	Forward primer for <u>insert</u> amplification (GO12) for insertion into site I2 (Illustr. 2,4). Further extension at 3' (rbs, insert specific overlap) required. Use with adaptor SacHind (multifragment SLIC, Illustr.4)
SacHind	GCTCGACTGGGAAA ACCCTGGCGAAGCTT	Reverse primer for <u>insert</u> amplification (GO12) insertion into MIE site I2 (Illustr. 2, 4). Further extension at 3' (stop codon, insert specific overlap) required. Use with adaptor BamSma (multifragment SLIC, Illustr.4)
HindSac	AAGCTTCGCCAGGGT TTTCCAGTCGAGC	Forward primer for <u>insert</u> amplification (GO13) for insertion into site I3 (Illustr. 2,4). Further extension at 3' (rbs, insert specific overlap) required. Use with adaptor BspEco (multifragment SLIC, Illustr.4)
BspEco5	GATCCGGATGTGAA ATTGTTATCCGCTGG TACC	Reverse primer for <u>insert</u> amplification (GO13) insertion into MIE site I3 (Illustr. 2, 4). Further extension at 3' (stop codon, insert specific overlap) required. Use with adaptor HindSac.(multifragment SLIC, Illustr.4)
Eco5Bsp	GGTACCAGCGGATA ACA ATTCACATCCGGAT C	Forward primer for <u>insert</u> amplification (GO14) for insertion into site I4 (Illustr. 2,4). Further extension at 3' (rbs, insert specific overlap) required. Use with adaptor XhoInsRev (multifragment SLIC, Illustr. 4)

¹ All Adaptor primers (without extension) can be used as sequencing primers for genes

of interest that were inserted into the MIE.

D.1.3. Gene insertion by restriction/ligation

The MIE can also be interpreted as a simple multiple cloning site with a series of unique restriction sites. The MIE is preceded by a promoter and a ribosome binding site, and followed by a terminator. Therefore, cloning into the MIE by classical restriction/ligation also yields functional expression cassettes.

Genes of interest can be subcloned by using standard cloning procedures into the multiple integration element (MIE) (see **Appendix**) of MultiColi™ vectors (the MIE is identical in all vectors).

Protocol 3. Restriction/ligation cloning into the MIE.

Reagents required:

- Phusion Polymerase
- 5x HF Buffer for Phusion Polymerase
- dNTP mix (10 mM)
- 10 mM BSA
- Restriction endonucleases (and 10x Buffer)
- T4 DNA ligase (and 10x Buffer)
- Calf or Shrimp intestinal alkaline phosphatase
- E. coli* competent cells
- Antibiotics

Step 1: Primer design

For conventional cloning, PCR primers are designed containing chosen restriction sites, preceded by appropriate overhangs for efficient cutting (c.f. New England Biolabs catalog), and followed by ≥ 20 nucleotides overlapping with the gene of interest that is to be inserted.

All MIEs are identical in the MultiColi™ vectors. They contain a ribosome binding site preceding the NdeI site. For single gene insertions, therefore, a rbs does not need be included in the primer.

If multi-gene insertions are planned (for example into insertion sites I1-I4 of the MIE), primers need to be designed such that a rbs preceding the gene and a stop codon at its end are provided.

In particular for polycistron cloning by restriction/ligation, it is recommended to construct templates by custom gene synthesis. In the process, the restriction sites present in the MIE can be eliminated from the encoding DNAs.

Step 2: Insert preparation

PCR of insert(s):

Identical PCR reactions are prepared in 100 µl volume for genes of interest to be inserted into the MIE:

ddH ₂ O	75 µl
5× Phusion HF Reaction buffer	20 µl
dNTPs (10 mM stock)	2 µl
Template DNA (100 ng/µl)	1 µl
5' primer (100 µM stock)	1 µl
3' primer (100 µM stock)	1 µl
Phusion polymerase (2 U/µl)	0.5 µl

PCR reactions are then carried out with a standard PCR program (unless very long DNAs are amplified, then double extension time):

1 x 98° C for 2 min

30 x [98° C for 20 sec. -> 50° C for 30 sec. -> 72° C for 3 min]

Hold at 10° C

Analysis of the PCR reactions by agarose gel electrophoresis and ethidium bromide staining is recommended.

Product purification is best performed by using commercial PCR Purification Kits or NucleoSpin Kits (Qiagen, MacheryNagel or others). It is recommended to perform elution in the minimal possible volume indicated by the manufacturer.

Restriction digestion of insert(s):

Restriction reactions are carried out in 40 µl reaction volumes, using the specific restriction enzymes as specified by the manufacturer's recommendations (c.f. New England Biolabs catalog and others).

PCR Kit eluate (≥1 µg)	30 µl
10x Restriction enzyme buffer	4 µl
10 mM BSA	2 µl
Restriction enzyme for 5'	2 µl
Restriction enzyme for 3'	2 µl

Restriction digestions are performed in a single reaction with both enzymes (double digestion) or sequentially (two single digestions) if the buffer conditions required are incompatible.

Gel extraction of insert(s):

Processed insert is then purified by agarose gel extraction using commercial kits (Qiagen, MachereyNagel etc). It is recommended to elute the extracted DNA in the minimal volume defined by the manufacturer.

Step 3: Vector preparation

Restriction digestion of MultiColi™ plasmid(s):

Restriction reactions are carried out in 40 µl reaction volumes, using specific restriction enzymes as specified by manufacturer's recommendations (c.f. New England Biolabs catalog and others).

MULTICOLI™ plasmid (≥0.5 µg) in	30 µl
ddH ₂ O	4 µl
10 mM BSA	2 µl
Restriction enzyme for 5'	2 µl
Restriction enzyme for 3'	2 µl (for double digestions, else ddH ₂ O)

Restriction digestions are performed in a single reaction with both enzymes (double digestion) or sequentially (two single digestions) if the buffer conditions required are incompatible.

Gel extraction of vector(s):

Processed vector is then purified by agarose gel extraction using commercial kits (Qiagen, MachereyNagel etc). It is recommended to elute the extracted DNA in the minimal volume defined by the manufacturer.

Step 4: Ligation

Ligation reactions are carried out in 20 µl reaction volumes according to the recommendations of the supplier of T4 DNA ligase:

MultiColi™ plasmid (gel extracted)	8 µl
Insert (gel extracted)	10 µl
10x T4 DNA Ligase buffer	2 µl
T4 DNA Ligase	0.5 µl

Ligation reactions are performed at 25°C (sticky end) for 1h or at 16°C (blunt end) overnight.

Step 5: Transformation

Mixtures are next transformed into competent cells following standard transformation procedures.

Reactions for pACE1 and pACE2 derivatives are transformed into standard *E. coli* cells for cloning (such as TOP10, DH5α, HB101) and after recovery plated on agar containing ampicillin (100 µg/ml) or tetracycline (25 µg/ml), respectively.

Reactions for Donor derivatives are transformed into *E. coli* cells expressing the *pir* gene (such as BW23473, BW23474, or PIR1 and PIR2, Invitrogen) and plated on agar containing chloramphenicol (25 µg/ml, pDC), kanamycin (50 µg/ml, pDK), and spectinomycin (50 µg/ml, pDS).

Step 6: Plasmid analysis

Plasmids are cultured and correct clones are selected based on specific restriction digestion and DNA sequencing of the inserts.

D.1.4. Multiplication by using the HE and BstXI sites

All MultiColi™ system vectors contain a homing endonuclease (HE) site and a designed BstXI site that envelop the multiple integration element (MIE). The homing endonuclease site can be used to insert entire expression cassettes, containing single genes or polycistrons, into a vector already containing one gene or several genes of interest. Homing endonucleases have long recognition sites (20-30 base pairs or more). Although not all equally stringent, homing endonuclease sites are most probably unique in the context of even large plasmids, or, in fact, entire genomes.

In the MultiColi™ system, Donor vectors contain a recognition site for homing endonuclease PI-SceI (**Illustr. 2**). This HE site yields upon cleavage a 3' overhang with the sequence -GTGC. Acceptor vectors contain the homing endonuclease site I-CeuI, which upon cleavage will result in a 3' overhang of -CTAA. On Acceptors and Donors, the respective HE site is preceding the MIE. The 3' end of the MIE contains a specifically designed BstXI site, which upon cleavage will generate a matching overhang. The basis of this is the specificity of cleavage by BstXI. The recognition sequence of BstXI is defined as CCANNNNN'NTGG (apostrophe marks position of phosphodiester link cleavage). The residues denoted as N can be chosen freely. Donor vectors thus contain a BstXI recognition site of the sequence CCATGTGC'CTGG, and Acceptor vectors contain CCATCTAA'TTGG. The overhangs generated by BstXI cleavage in each case will match the overhangs generated by HE cleavage. Note that Acceptors and Donors have different HE sites.

The recognition sites are not symmetric. Therefore, ligation of a HE/BstXI digested fragment into a HE site of an MultiColi™ vector will be (1) directional and (2) result in a hybrid DNA sequence where a HE halfsite is combined with a BstXI halfsite. This site

will be cut by neither HE nor BstXI. Therefore, in a construct that had been digested with a HE, insertion by ligation of HE/BstXI digested DNA fragment containing an expression cassette with one or several genes will result in a construct which contains all heterologous genes of interest, enveloped by an intact HE site in front, and a BstXI site at the end. Therefore, the process of integrating entire expression cassettes by means of HE/BstXI digestion and ligation into a HE site can be repeated iteratively.

Protocol 4. Multiplication by using homing endonuclease/BstXI.

Reagents required:

- Homing endonucleases PI-SceI, I-CeuI
- 10x Buffers for homing endonucleases
- Restriction enzyme BstXI (and 10x Buffer)
- T4 DNA ligase (and 10x Buffer)
- E. coli* competent cells
- Antibiotics

Step 1: Insert preparation

Restriction reactions are carried out in 40 µl reaction volumes, using homing endonucleases PI-SceI (Donors) or I-CeuI (Acceptors) as recommended by the supplier (c.f. New England Biolabs catalog and others).

MultiColi™ plasmid (≥ 0.5 µg) in ddH ₂ O	32 µl
10x Restriction enzyme buffer	4 µl
10 mM BSA	2 µl
PI-SceI (Donors) or I-CeuI (acceptors)	2 µl

Reactions are then purified by PCR extraction kit or acidic ethanol precipitation, and next digested by BstXI according to the recommendations of the supplier.

HE digested DNA in ddH ₂ O	32 µl
10x Restriction enzyme buffer	4 µl
10 mM BSA	2 µl
BstXI	2 µl

Gel extraction of insert(s):

Processed insert is then purified by agarose gel extraction using commercial kits

(Qiagen, MachereyNagel etc). It is recommended to elute the extracted DNA in the minimal volume defined by the manufacturer.

Step 2: Vector preparation

Restriction reactions are carried out in 40 μ l reaction volumes, using homing endonucleases PI-SceI (Donors) or I-CeuI (Acceptors) as recommended by the supplier (c.f. New England Biolabs catalog and others).

MultiColi™ plasmid ($\geq 0.5 \mu\text{g}$) in ddH ₂ O	33 μ l
10x Restriction enzyme buffer	4 μ l
10 mM BSA	2 μ l
PI-SceI (Donors) or I-CeuI (acceptors)	1 μ l

Reactions are then purified by PCR extraction kit or acidic ethanol precipitation, and next treated with intestinal alkaline phosphatase according to the recommendations of the supplier.

HE digested DNA in ddH ₂ O	17 μ l
10x Alkaline phosphatase buffer	2 μ l
Alkaline phosphatase	1 μ l

Gel extraction of vector:

Processed vector is then purified by agarose gel extraction using commercial kits (Qiagen, MachereyNagel etc). It is recommended to elute the extracted DNA in the minimal volume defined by the manufacturer.

Step 3: Ligation

Ligation reactions are carried out in 20 μ l reaction volumes:

HE/Phosphatase treated vector (gel extracted)	4 μ l
HE/BstXI treated insert (gel extracted)	14 μ l
10x T4 DNA Ligase buffer	2 μ l
T4 DNA Ligase	0.5 μ l

Ligation reactions are performed at 25°C for 1h or at 16°C overnight.

Step 4: Transformation

Mixtures are next transformed into competent cells following standard transformation procedures.

Reactions for pACE and pACE2 derivatives are transformed into standard *E. coli* cells for cloning (such as TOP10, DH5 α , HB101) and after recovery plated on agar containing ampicillin (100 $\mu\text{g}/\text{ml}$) or tetracycline (25 $\mu\text{g}/\text{ml}$), respectively.

Reactions for Donor derivatives are transformed into *E. coli* cells expressing the *pir* gene (such as BW23473, BW23474, or PIR1 and PIR2, Invitrogen) and plated

on agar containing chloramphenicol (25 µg/ml, pDC), kanamycin (50 µg/ml, pDK), and spectinomycin (50 µg/ml, pDS).

Step 5: Plasmid analysis

Plasmids are cultured and correct clones selected based on specific restriction digestion and DNA sequencing of the inserts.

Note: Integration can likewise be performed by sequence and ligation independent cloning. It is recommended to carry out linearization of the vector by digestion with HE, if heterologous genes are already present, to avoid PCR amplifications over encoding regions. The fragment to be inserted is generated by PCR amplification resulting in a PCR fragment containing a 20-25 base pair stretch at its 5' end that is identical to the corresponding DNA sequence present at the HE site counted from the site of cleavage towards 5' (site of cleavage is position -4). At the 3' end of the PCR fragment, the homology region is 20-25 base pairs counted from the site of cleavage towards 3'.

D.2. Cre-LoxP reaction of Acceptors and Donors

Cre recombinase is a member of the integrase family (Type I topoisomerase from bacteriophage P1). It recombines a 34 bp loxP site in the absence of accessory protein or auxiliary DNA sequence. The loxP site is comprised of two 13 bp recombinase-binding elements arranged as inverted repeats which flank an 8 bp central region where cleavage and ligation reaction occur.

The site-specific recombination mediated by Cre recombinase involves the formation of a Holliday junction (HJ). The recombination events catalyzed by Cre recombinase are dependent on the location and relative orientation of the loxP sites. Two DNA molecules, for example an Acceptor and a Donor plasmid, containing single loxP sites will be fused. Furthermore, the Cre recombination is an equilibrium reaction with 20-30% efficiency in recombination. This provides useful options for multi-gene combinations for multi-protein complex expression.


Illustration 7: LoxP imperfect inverted repeat

13bp	8bp	13bp
5'...ATAACTTCGTATA	GCATACAT	TATACGAAGTTAT...3'
3'...TATTGAAGCATAT	CGTATGTA	ATATGCTTCAATA...5'
inverted repeat	Spacer	inverted repeat

In a reaction where several DNA molecules such as Donors and Acceptors are incubated with Cre recombinase, the fusion/excision activity of the enzyme will result in an equilibrium state where single vectors (educt vectors) and all possible fusions coexist. Donor vectors can be used with Acceptors and/or Donors, likewise for Acceptor vectors. Higher order fusions are also generated where more than two vectors are fused. This is shown schematically in **Illustration 8**.

The fact that Donors contain a conditional origin of replication that depends on a *pir*⁺ (*pir* positive) background now allows for selecting out from this reaction mix all desired Acceptor-Donor(s) combinations. For this, the reaction mix is used to transform to *pir* negative strains (TOP10, DH5 α , HB101 or other common laboratory cloning strains). Then, Donor vectors will act as suicide vectors when plated out on agar containing the antibiotic corresponding to the Donor encoded resistance marker, unless fused with an Acceptor. By using agar with the appropriate combinations of antibiotics, all desired Acceptor-Donor fusions can be selected for.

Using this approach, fusion vectors of 25 kb and larger have generated. In stability tests (serial passaging for more than 60 generations), even such large plasmids proved to be stable as checked by restriction mapping, even if only one of the antibiotics corresponding to the encoded resistance markers was provided in the growth medium.

Illustration 8: Cre and De-Cre reaction pyramid

D.2.1. Cre-LoxP fusion of Acceptors and Donors

This protocol is designed for generating multi-gene fusions from Donors and Acceptors by Cre-LoxP reaction.

Reagents:

- Cre recombinase (from NEB or self made)
- Standard *E. coli* competent cells (*pir*⁻ strain)
- Antibiotics
- 96well microtiter plates
- 12 well tissue-culture plates (or petri dishes) w. agar/antibiotics
- LB medium

1. For a 20µl Cre reaction, mix 1-2 µg of each educt in approximately equal amounts. Add ddH₂O to adjust the total volume to 16-17 µl, then add 2 µl 10x Cre buffer and 1-2µl Cre recombinase.
2. Incubate Cre reaction at 37°C (or 30°C) for 1 hour.
3. Optional: load 2-5 µl of Cre reaction on an analytical agarose gel for examination.

Heat inactivation at 70°C for 10 minutes before the gel loading is strongly recommended.

4. For chemical transformation, mix 10-15µl Cre reaction with 200 µl chemical competent cells. Incubate the mixture on ice for 15-30 minutes. Then perform heat shock at 42°C for 45-60 s.

Up to 20 µl Cre reaction (0.1 volumes of the chemical competent cell suspension) can be directly transformed into 200 µl chemical competent cells.

For electrotransformation, up to 2 µl Cre reaction could be directly mixed with 100 µl electrocompetent cells, and transformed by using an electroporator (e.g. BIORAD E. coli Pulser) at 1.8-2.0 kV.

Larger volume of Cre reaction must be desalted by ethanol precipitation or PCR purification column before electrotransformation. The desalted Cre reaction mix should not exceed 0.1 volumes of the electrocompetent cell suspension.

The cell/DNA mixture could be immediately used for electrotransformation without prolonged incubation on ice.

5. Add up to 400 µl of LB media (or SOC media) per 100 µl of cell/DNA suspension immediately after the transformation (heat shock or electroporation).
 6. Incubate the suspension in a 37°C shaking incubator overnight or for at least 4 hours (recovery period).
- For recovering multifusion plasmid containing more than 2 resistance markers, it is strongly recommended to incubate the suspension at 37°C overnight.*
7. Plate out the recovered cell suspension on agar containing the desired combination of antibiotics. Incubate at 37°C overnight.
 8. Clones from colonies present after overnight incubation can be verified by restriction digestion at this stage (refer to steps 12-16).

Especially in the case that only one multifusion plasmid is desired.


For further selection by single antibiotic challenges on a 96 well microtiter plate, continue to step 9.

Several to many different multifusion plasmid combinations can be processed and selected on one 96 well microtiter plate in parallel.

9. For 96 well antibiotic tests, inoculate four colonies from each agar plate with different antibiotic combination into ~500 μ l LB media without antibiotics. Incubate the cell cultures in a 37°C shaking incubator for 1-2 hours.
10. During the incubation of colonies, fill a 96 well microtiter plate with 150 μ l antibiotic-containing LB media (following Illustration 7). It is recommended to add coloured dye (positional marker) in the wells indicated.

A typical arrangement of the solutions, which is used for parallel selections of multifusion plasmids, is shown in Illustration 9. The concept behind the 96 well plate experiment is that every cell suspension from single colonies needs to be challenged by all four single antibiotics for unambiguous interpretation.

Illustration 9: 96 well analysis of Cre assembly



11. Add 1 μ l aliquots of pre-incubated cell culture (Step 9) to the corresponding wells. Then incubate the inoculated 96 well microtiter plate in a 37°C shaking incubator overnight at 180-200 rpm.

Recommended: use parafilm to wrap the plate to avoid drying out.

The remainder of the pre-incubated cell cultures could be kept at 4°C for further inoculations if necessary.

12. Select transformants containing desired multifusion plasmids based on antibiotic resistance, according to the combination of dense (positive) and clear (no growth) cell microcultures from each colony. Inoculate 10-20 μ l cell culture into 10 ml LB media with corresponding antibiotics. Incubate in a 37°C shaking incubator overnight.
13. Centrifuge the overnight cell cultures at 4000g for 5-10 minutes. Purify plasmid from the resulting cell pellets with common plasmid miniprep kits, according to manufacturers' recommendation.
14. Determine the concentrations of purified plasmid solutions by using UV absorption spectroscopy (e.g. by using a NanoDrop™ 1000 machine).
15. Digest approx. 0.5-1 μ g of the purified plasmid solution in a 20 μ l restriction digestion with appropriate endonuclease(s). Incubate under recommended reaction condition for ~2 hours.
16. Use 5-10 μ l of the digestion for analytical agarose (0.8-1.2%) gel electrophoresis. Verify plasmid integrity by comparing the experimental restriction pattern to a restriction pattern predicted *in silico* (e.g. by using program VectorNTI from Invitrogen or similar programs).

D.2.2. Deconstruction of fusion vectors by Cre

The protocol is suitable for releasing any single educt from multifusion constructs (deconstruction). This is achieved by Cre-LoxP reaction, transformation and plating on agar with appropriately reduced antibiotic resistance level (c.f. Illustration 8). In the liberated educt entity, encoding genes can be modified and diversified. Then, the diversified construct is resupplied by Cre-LoxP reaction (**C.2.1.**).

Reagents:

Cre recombinase (and 10x Buffer)

E. coli competent cells

(*pir*⁺ strains, *pir*⁻ strains could be used only when partially deconstructed Acceptor-Donor fusions are desired).

Antibiotics

1. Incubate approx. 1 μ g multifusion plasmid with 2 μ l 10x Cre buffer, 1-2 μ l Cre recombinase, add ddH₂O to adjust the total reaction volume to 20 μ l.
2. Incubate this Cre deconstruction reaction mixture at 30°C for 1-4 hour.
3. Optional: load 2-5 μ l of the reaction on an analytical agarose gel for examination.

Heat inactivation at 70°C for 10 minutes before the gel loading is strongly recommended.

4. For chemical transformation, mix 10-15µl De-Cre reaction with 200 µl chemical competent cells. Incubate the mixture on ice for 15-30 minutes. Then perform heat shock at 42°C for 45-60 s.

Up to 20 µl De-Cre reaction (0.1 volumes of the chemical competent cell suspension) can be directly transformed into 200 µl chemical competent cells.

For electrotransformation, up to 2 µl De-Cre reaction can be directly mixed with 100 µl electrocompetent cells, and transformed by using an electroporator (e.g. BIORAD *E. coli* Pulser) at 1.8-2.0 kV.

Larger volume of De-Cre reaction must be desalted by ethanol precipitation or PCR purification column before electrotransformation. The desalted De-Cre reaction mix should not exceed 0.1 volumes of the electrocompetent cell suspension.

The cell/DNA mixture could be immediately used for electrotransformation without prior incubation on ice.

5. Add up to 400 µl of LB media (or SOC media) per 100 µl of cell/DNA suspension immediately after the transformation (heat shock or electroporation).

6. Incubate the suspension in a 37°C shaking incubator (recovery).

For recovery of partially deconstructed double/triple fusions, incubate the suspension in a 37°C shaking incubator for 1 to 2 hours.

For recovery of individual educts such as single MultiColi™ vectors from pACKS plasmid, incubate the suspension in a 37°C shaking incubator overnight or for at least 4 hours.

7. Plate out the recovered cell suspension on agar containing the desired (combination of) antibiotic(s). Incubate at 37°C overnight.
8. Colonies after overnight incubation might be verified directly by restriction digestion at this stage (refer to steps 12-16).

Especially recommended in the case that only one single educt or partially deconstructed multifusion plasmid is desired.

For further selection by single antibiotic challenge on a 96 well microtiter plate, continue with step 9.

Several different single educts/partially deconstructed multifusion plasmids can be processed and selected on one 96 well microtiter plate in parallel.

9. For 96 well analysis, inoculate four colonies each from agar plates containing a defined set of antibiotics into ~500 µl LB media without antibiotics. Incubate the cell cultures in a 37°C shaking incubator for 1-2 hours.
10. During the incubation of colonies, fill a 96 well microtiter plate with 150 µl antibiotic-containing LB media or coloured dye (positional marker) in the corresponding wells.

Refer to Illustrations 9 and 14 for the arrangement of the solutions in the wells, which are used for parallel selection of single educts or partially deconstructed multifusion plasmids. The concept is that every cell suspension from a single colony needs to be challenged by all four antibiotics separately for unambiguous interpretation.

11. Add 1 μ l aliquots from the pre-incubated cell cultures (Step 9) into the corresponding wells. Then incubate the 96 well microtiter plate in a 37°C shaking incubator overnight at 180-200 rpm.

Recommended: use parafilm to wrap the plate to prevent desiccation.

The remainder of the pre-incubated cell cultures can be kept in 4°C fridge for further inoculations if necessary.

12. Select transformants containing desired single educts or partially deconstructed multifusion plasmids according to the combination of dense (growth) and clear (no growth) cell cultures from each colony. Inoculate 10-20 μ l cell cultures into 10 ml LB media with corresponding antibiotic(s). Incubate in a 37°C shaking incubator overnight.
13. Centrifuge the overnight cell cultures at 4000g for 5-10 minutes. Purify plasmid from cell pellets with common plasmid miniprep kits, according to manufacturers' information.
14. Determine the concentrations of purified plasmid solutions by using UV absorption spectroscopy (e.g. NanoDrop™ 1000).
15. Digest approx. 0.5-1 μ g of the purified plasmid solution in a 20 μ l restriction digestion (with 5-10 unit endonuclease). Incubate under recommended reaction condition for ~2 hours.
16. Use 5-10 μ l of the digestion for analytical agarose gel (0.8-1.2%) electrophoresis. Verify the plasmid integrity by comparing the actual restriction pattern to predicted restriction pattern *in silico* (e.g. by using VectorNTI, Invitrogen, or any other similar program).
17. Optional: Possibly, a deconstruction reaction is not complete but yields partially deconstructed fusions which still retain entities to be eliminated. In this case, we recommend to pick these partially deconstructed fusions containing and perform a second round of Cre deconstruction reaction (repeat steps 1-8) by using this construct as starting material.

In our hands, two sequential deconstruction reactions were always sufficient to recover all individual modules, for instance all four single MultiColi™ vectors from a pACKS plasmid. Liberation of single educts from double/triple fusions were found to be often more efficient than from quadruples such as the pACKS plasmid of the system kit (Section E).

D.3. Co-expression by Co-transformation

Protein complexes can be expressed also from two separate vectors co-transformed in expression strains. The co-transformed vectors can have the same or different origins of replication, however, they must encode different resistance markers.

Plasmids pACE1 (ampicillin resistance marker) and pACE2 (tetracycline resistance marker) have both a ColE1-derived replicon and can therefore be used with all common expression strains. pACE1 and pACE2 derivatives (also including fused Donors if needed) can be co-transformed into expression strains, and double transformants selected for by plating on agar plates containing both ampicillin and tetracyclin antibiotics.

Transformations are carried out by using standard transformation protocols.

Please note though that the system has not been optimized for co-transformation. Actually, co-transformation more or less defeats the purpose of the recombineering approach that MultiColi™ takes. MultiColi™ has been developed to avoid the inconsistencies that can accompany co-transformation of multiple plasmid constructs by allowing you to build polycistronic assemblies and concatemers.


E. MultiColi™ multi-gene combination: Examples

Examples of multi-protein expressions by MultiColi™ illustrating the gene combination procedures detailed in Section C are shown in the following. Reactions presented were carried out manually following the protocols provided, and also on a Tecan Freedom Evoll 200 robot with adapted protocols. These and other examples have been published in Bieniossek et al., *Nat. Methods* **6**, 447 (2009) plus supplementary material.

E.1. SLIC cloning into MultiColi™ vectors: human TFIIF

Genes encoding full-length human RAP74 with a C-terminal oligo-histidine tag and full-length human RAP30¹⁶ were amplified from pET-based plasmid template¹⁶ following the protocols described above. Linearized vector backbones were generated by PCR amplification from pACE1 and pDC. SLIC following Protocol 1 (Section D), yielded pACE1-RAP30 and pDC-RAP74his (Fig 8). These plasmids were fused by Cre-LoxP reaction (Section C). Results from restriction mapping by BstZ171/BamHI double digestion of 11 double resistant (Cm, Ap) colonies are shown by a gel section from 1% E-gel electrophoresis (M: NEB 1kb DNA marker). All clones tested showed the expected pattern (5.0 + 2.8 kb). One clone was transformed in BL21(DE3) cells. Expression and purification by Ni²⁺-capture and S200 chromatography resulted in human TFIIF complex.

Illustration 10: MultiColi™ TFIIF (Image courtesy of Dr. I. Berger, EMBL Grenoble).




¹⁶ Gaiser, Tan and Richmond, *J. Mol. Biol.* **302**, 1119 (2000).

E.2. The Homing endonuclease/BstXI module: yeast RES complex

Plasmids pCDFDuet-Pml1p, pRSFDuet-Snu17p-NHis and pETDuet-Bud13p, encoding for yeast proteins (all full-length) Pml1p, Snu17p and Bud13p, respectively, were a kind gift from Dr. Simon Trowitzsch and Dr. Markus Wahl (MPI Göttingen). Snu17p contains a six-histidine tag fused to its N-terminus. The gene encoding for His6-tagged Snu17p was excised from pRSFDuet-Snu17p-NHis by NcoI/XhoI restriction, and ligated into a NcoI/XhoI digested pACE1 construct (containing an unrelated gene between the NcoI and XhoI sites) resulting in pACE1-Snu17. The gene encoding for Bud13p was liberated from pETDuet-Bud13p by restriction digestion with XbaI and EcoRV, and placed into XbaI/PmeI digested pDC resulting in pDC-Bud13. The gene encoding Pml1p was liberated from pCDFDuet-Pml1p by restriction digestion with NdeI and XhoI, and placed into NdeI/XhoI digested pDC resulting in pDC-Pml1. Next, the expression cassette for Bud13p was liberated from pDC-Bud13 by digestion with P1-SceI and BstXI. The liberated fragment was inserted into P1-SceI digested and alkaline phosphatase treated pDC-Pml1p resulting in pDC-Bud13p-Pml1p. pACE-Snu17 and pDC-BudPml were then fused by Cre-LoxP reaction and selected for by plating on agar plates containing ampicillin and chloramphenicol. Fusion plasmids were transformed into BL21(DE3) cells. Expression and purification by Ni²⁺-capture and S200 size exclusion chromatography resulted in the trimeric RES complex.


Illustration 11: The HE/BstXI multiplication module.



F. Appendix

F.1. DNA sequence of MIE

Below are the sequence and map of the MIE fragment between T7/lac promoter and T7 terminator in MultiColi™ vectors. Forward and reverse primers for sequencing can be standard vector primers for T7 and lac. Adaptor primer sequences (c.f. Table I) are indicated. DNA sequences in these homology regions contain tried-and-tested sequencing primers¹⁷¹⁷. Sites of insertion (I1-I4) are shown below. The adaptor sequences, and probably any sequence in the homology regions, can be used as adaptors for multifragment insertions. The ribosome binding site present in the MIE (rbs) is boxed in red.




¹⁷ Tan S et al. *Protein Expr. Purif.* **40**, 385 (2005)

F.2. DNA sequences of MultiColi™ vectors

Below are the complete sequences of all acceptor and donor vectors.

Please note though that copy-pasting from a PDF may result in faulty data transfer into other applications, i.e. DNA sequences may lack base pairs. To avoid any trouble, simply request the vector sequence data from www.geneva-biotech.com. We will provide them either in text format or as ApE files that will give you ample annotation of the features contained on the vectors. The ApE plasmid editor can be downloaded for free from its author's web site (M. Wayne Davis, University of Utah).


F.3. MultiColi™ plasmid maps



Acceptor vectors pACE1 (pACE) and pACE2, containing a T7 promoter and terminator, are shown. **Donor vectors** pDK, pDS and pDC contain conditional origins of replication. pDS and pDK have a lac promoter. pDC has a T7 promoter. Resistance markers are shown in gray, origins of replication in yellow. LoxP imperfect inverted repeat sequences are shown as spheres. Homing endonuclease sites and corresponding BstXI sites are boxed. The restriction enzyme sites in the multiple integration element (MIE) are indicated. All MIEs have the same DNA sequence between Clal and PmeI. Differences in unique restriction site composition stem from differences in the plasmid backbone sequences.

F.4. Analytical restriction of MultiColi™ vectors

All MultiColi™ vectors were analyzed by BamHI restriction digestion. The undigested and digested MultiColi™ vectors are shown below:



Restriction mapping of MultiColi™ vectors. Both undigested as well as BamHI-digested Acceptor and Donor vectors are. All restriction reactions yield the expected sizes. Lane 1-5 show uncut pACE1, pACE2, pDC, pDK, and pDS vectors; lane M shows λ Styl marker; lane A-E show BamHI- digested pACE1, pACE2, pDC, pDK, and pDS vectors.

Additionally, the MultiColi™ vectors yield characteristic restriction digest patterns when plasmid DNA is restricted with HindIII and HinfI.

Vector	Length [bp]	Restriction	Fragment(s) [bp]
pACE1	2652	HindIII	2652
		HinfI	1690, 491, 396, 75
pACE2	2982	HindIII	2982
		HinfI	772, 618, 491, 396, 256, 220, 154, 75
pDC	2033	HindIII	1483, 550
		HinfI	1275, 758
		HindIII+HinfI	758, 597, 550, 128
pDK	2077	HindIII	1681, 396
		HinfI	1796, 134, 58, 52, 37
pDS	2027	HindIII	1631, 396
		HinfI	1814, 213
		HindIII+HinfI	813, 605, 396, 213

G. References

1. **Alberts B** (1998). The cell as a collection of protein machines: preparing the next generation of molecular biologists. *Cell* 92: 291-294.
2. **Ausubel F, Brent R, et al.** (eds., 1994). Current Protocols in Molecular Biology. John Wiley & Sons, New York, electronic version DOI 10.1002/0471142727
3. **Bhattacharya A** (2009). Protein structure: Structures of desire. *Nature* 459: 24-27.
4. **Bieniossek C, Nie Y, Frey D, Olieric N, Schaffitzel C, Collinson I, Romier C, Berger P, Richmond TJ, Steinmetz MO, Berger I** (2009). Automated unrestricted multigene recombineering for multiprotein complex production. *Nature Methods* 6: 447-450.
5. **Charbonnier S, Gallego O, Gavin AC** (2008). The social network of a cell: Recent advances in interactome mapping. *Biotechnology Annual Review* 14: 1-28.
6. **Chemler JA and Koffas MAG** (2008). Metabolic engineering for plant natural product biosynthesis in microbes. *Current Opinion in Biotechnology* 19: 597-605.
7. **Chou CP** (2007). Engineering cell physiology to enhance recombinant protein production in *Escherichia coli*. *Applied Microbiology and Biotechnology* 76: 521-532.
8. **Estrozi LF, Boehringer D, Shan SO, Ban N, Schaffitzel C** (2011). Cryo-EM structure of the E. coli translating ribosome in complex with SRP and its receptor. *Nature Structural and Molecular Biology* 18: 88-90.
9. **Gaiser F, Tan S, and Richmond TJ** (2000). Novel dimerization fold of RAP30/RAP74 in human TFIIF at 1.7 Å resolution. *Journal of Molecular Biology* 302: 1119-1127.
10. **Inoue H, Nojima H and Okayama H** (1990). High efficiency transformation of *Escherichia coli* with plasmids. *Gene* 96: 23-28.
11. **Lee SK, Chou H, Ham TS, Lee TS, and Keasling JD** (2008). Metabolic engineering of microorganisms for biofuels production: from bugs to synthetic biology to fuels. *Current Opinion in Biotechnology* 19: 556-563.
12. **Li M and Elledge SJ** (2007). Harnessing homologous recombination in vitro to generate recombinant DNA via SLIC. *Nature Methods* 4: 251-256.
13. **Nie Y, Viola C, Bieniossek C, Trowitzsch S, Vijay-Achandran LS, Chaillet M, Garzoni F, Berger I** (2009). Getting a grip on complexes. *Current Genomics* 10: 558-72.
14. **Robinson CV, Sali A, and Baumeister W** (2007). The molecular sociology of the cell. *Nature* 450: 973-982.
15. **Sambrook J and Russell DW** (2000). Molecular Cloning, A Laboratory Manual, 3rd edition. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, available online at <http://cshprotocols.cshlp.org>
16. **Tan S, Kern RC, and Selleck W** (2005). The pST44 polycistronic expression system for producing protein complexes in *Escherichia coli*. *Protein Expression and Purification* 40: 385-395.
17. **Van Hijum SA, Medema MH, and Kuipers OP** (2009). Mechanisms and evolution of control logic in prokaryotic transcriptional regulation. *Microbiology and Molecular Biology Reviews* 73: 481-509.

H. Purchaser Notification

Limited Use Label License : Geneva Biotech

The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for-profit entity).

The buyer cannot sell or otherwise transfer **(a)** this product **(b)** its components or **(c)** materials made using this product or its components to a third party or otherwise use this product or its components or materials made using this product or its components for Commercial Purposes. The buyer may transfer information or materials made through the use of this product to a scientific collaborator, provided that such transfer is not for any Commercial Purpose, and that such collaborator agrees in writing **(a)** not to transfer such materials to any third party, and **(b)** to use such transferred materials and/or information solely for research and not for Commercial Purposes.

Commercial Purposes means any activity by a party for consideration and may include, but is not limited to: **(1)** use of the product or its components in manufacturing; **(2)** inclusion of the product as part of another product; **(3)** use of the product or its components to provide a service, information, or data; **(4)** use of the product or its components for *ex vivo* or *in vivo* therapeutic, diagnostic, prophylactic or other unauthorized commercial purposes; **(5)** use in foods, drugs, devices or cosmetics of any kind, or for consumption by or use in connection with or administration or application to humans or animals; **(6)** resale of the product or its components, whether or not such product or its components are resold for use in research, or **(7)** any use other than research use.

For products that are subject to multiple limited use label licenses, the terms of the most restrictive limited use label license shall control. Geneva Biotech will not assert a claim against the buyer of infringement of patents owned or controlled by Geneva Biotech which cover this product based upon the manufacture, use or sale of a therapeutic, clinical diagnostic, vaccine or prophylactic product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product.

If the purchaser does not agree with the terms or limitations of this limited use agreement, the customer can return the product at their own costs but for a full refund (excluding shipping, tax and handling fees).

For information about purchasing a license to use this product or the technology embedded in it for any use other than for research use please contact Geneva Biotech at contact@geneva-biotech.com